The discovery of MK-4256, a potent SSTR3 antagonist as a potential treatment of type 2 diabetes

ACS Medicinal Chemistry Letters

Volumn 3, Issue 6, 2012, Pages 484-489

  He, Shuwen ^a   Ye, Zhixiong ^a   Truong, Quang ^a   Shah, Shrenik ^a   Du, Wu ^a   Guo, Liangqin ^a   Dobbelaar, Peter H ^a   Lai, Zhong ^a   Liu, Jian ^a   Jian, Tianying ^a   Qi, Hongbo ^a   Bakshi, Raman K ^a   Hong, Qingmei ^a   Dellureficio, James ^a   Pasternak, Alexander ^a   Feng, Zhe ^a   Dejesus, Reynalda ^a   Yang, Lihu ^a   Reibarkh, Mikhail ^a   Bradley, Scott A ^a   Holmes, Mark A ^a   Ball, Richard G ^a   Ruck, Rebecca T ^a   Huffman, Mark A ^a   Wong, Frederick ^a   Samuel, Koppara ^a   Reddy, Vijay B ^a   Mitelman, Stan ^a   Tong, Sharon X ^a   Chicchi, Gary G ^a   Tsao, Kwei Lan ^a   Trusca, Dorina ^a   Wu, Margaret ^a   Shao, Qing ^a   Trujillo, Maria E ^a   Eiermann, George J ^a   Li, Cai ^a   Zhang, Bei B ^a   Howard, Andrew D ^a   Zhou, Yun Ping ^a   Nargund, Ravi P ^a   Hagmann, William K ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

tetrahydrocarboline; antagonist; SSTR3; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CARBOLINE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GLIPIZIDE; IMIDAZOLYL BETA TETRAHYDROCARBOLINE DERIVATIVE; MK 4256; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; IC 50; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 84862294249     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300063m     Document Type: Article

References (26)

1. Del Prato, S.; Marchetti, P.; Bonadonna, R. C. Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes Diabetes 2002, 51 (Suppl. 1) S109-S116
2. Shaw, J. E.; Sicree, R. A.; Zimmet, P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res. Clin. Pract. 2010, 87, 4-14
3. Gonzalez, E. L.; Johansson, S.; Wallander, M. A.; Rodriguez, L. A. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005 J. Epidemiol. Community Health 2009, 63, 332-336
4. Scanlon, P. H. The English national screening programme for sight-threatening diabetic retinopathy J. Med. Screen. 2008, 15 (1) 1-4 (Pubitemid 351629537)
5. Palmer, A. J.; Valentine, W. J.; Chen, R.; Mehin, N.; Gabriel, S.; Bregman, B.; Rodby, R. A. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA Nephrol., Dial., Transplant. 2008, 23, 1216-1223 (Pubitemid 351767535)
6. Petrie, J. R.; Adler, A.; Vella, S. What to add in with metformin in type 2 diabetes? Q. J. Med. 2011, 104, 185-192
7. Kokil, G. R.; Rewatkar, P. V.; Verma, A.; Thareja, S.; Naik, S. R. Pharmacology and Chemistry of Diabetes mellitus and Antidiabetic Drugs: A Critical Review Curr. Med. Chem. 2010, 17, 4405-4423
8. Krentz, A. J.; Patel, M. B.; Bailey, C. J. New drugs for type 2 diabetes mellitus: What is their place in therapy? Drug 2008, 68 (15) 2131-2162
9. Butler, A. E.; Janson, J.; Bonner-Weir, S.; Ritzel, R.; Rizza, R. A.; Butler, P. C. β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes Diabetes 2003, 52 (1) 102-110 (Pubitemid 36042113)
10. Bodmer, M; Meier, C.; Krähenbühl, S.; Jick, S. S.; Meier, C. R. Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia, A nested case-control analysis Diabetes Care 2008, 31 (11) 2086-2091
11. Weber, A. E. Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes J. Med. Chem. 2004, 47, 4135-4141 (Pubitemid 39045417)
12. Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes, Obes. Metab. 2011, 13, 7-18
13. Olias, G.; Viollet, C.; Kusserow, H.; Epelbaum, J.; Meyerhof, W. Regulation and function of somatostatin receptors J. Neurochem. 2004, 89, 1057-1091 (Pubitemid 38720193)
14. Li, J.; Zhou, Y.; Manuscript in preparation.
15. Pasternak, A.; Feng, Z.; deJesus, R.; Ye, Z.; He, S.; Dobbelaar, P. H.; Bradley, S. A; Chicchi, G. G.; Tsao, K.; Trusca, D.; Eiermann, G. J.; Feng, Y.; Wu, M.; Shao, Q.; Zhang, B.; Nargund, R. P.; Mills, S. G.; Howard, A. D.; Yang, L.; Zhou, Y. Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist ACS Med. Chem. Lett. 2012, 3, 289-293
16. Ahrén, B. GLP-1 for type 2 diabetes Exp. Cell Res. 2011, 317, 1239-1245
17. Poitout, L.; Roubert, P.; Contour-Galcera, M.; Moinet, C.; Lannoy, J.; Pommier, J.; Plas, P.; Bigg, D.; Thurieau, C. Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity J. Med. Chem. 2001, 44, 2990
18. Thurieau, C.; Poitout, L.; Galcera, M.; Moinet, C; Gordon, T. D.; Morgan, B. A.; Bigg, D.; Pommier, J. β-Carboline Compounds. WO 1999/64420, December 16, 1999.
19. Troxler, T.; Hurth, K.; Hoyer, D. Beta-Carboline Derivatives and Its Pharmaceutical Use Against Depression and Anxiety. WO 2002/081471, April 2, 2002.
20. Troxler, T.; Hurth, K.; Schuh, K.; Schoeffter, P.; Langenegger, D.; Enz, A.; Hoyer, D. Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists Bioorg. Med. Chem. Lett. 2010, 20, 1728-1734
21. Baenziger, M.; Cercus, J.; Hirt, H.; Laumen, K.; Malan, C.; Spindler, F.; Struber, F.; Troxler, T. The development of a practical synthesis of the potent and selective somatostatin sst3 receptor antagonist [4-(3,4-difluoro-phenyl)- piperazine-1-yl]-{(4S,4aS,8aR)-2[(S)-3-(6-methoxy-pyridin-3-yl)-2-methyl-propyl] -decahydroisoquinoline-4-yl}-methanone (NVP-ACQ090) Tetrahedron: Asymmetry 2003, 14, 3469-3477 (Pubitemid 37412469)
22. Raab, C. E.; Butcher, J. W.; Connolly, T. M.; Karczewski, J.; Yu, N. X.; Staskiewicz, S. J.; Liverton, N.; Dean, D. C.; Melillo, D. G. Synthesis of the first sulfur-35-labeled hERG radioligand Bioorg. Med. Chem. Lett. 2006, 16, 1692-1695 (Pubitemid 43197547)
23. Wang, J.; Della Penna, K.; Wang, H.; Karczewski, J.; Connolly, T. M.; Koblan, K. S.; Bennett, P. B.; Salata, J. J. Functional and pharmacological properties of canine ERG potassium channels Am. J. Phys 2003, 284, H256-H267
24. He, S.; Lai, Z.; Yang, D. X.; Hong, Q.; Reibarkh, M.; Nargund, R. P.; Hagmann, W. K. Synthesis of β-carboline from aldehydes and ketones via the α-siloxy-α,β-unsaturated esters Tetrahedron Lett. 2010, 51, 4361-4364 and references therein
25. Li, C.; Manuscript in preparation.
26. Process chemistry for the first GMP delivery of MK-4256 has been disclosed recently: Ruck, R. T.; Huffman, M. A.; Stewart, G.; Cleator, E.; Kandur, W. A.; Kim, M. M.; Zhao, D. Process chemistry for the first GMP delivery of SSTR3 antagonist MK-4256. Abstracts of Papers, Presentation (ORGN-461), 243rd ACS National Meeting, San Diego, CA, March 25-29, 2012.